Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib
Keyword(s):
2016 ◽
Vol 11
(11)
◽
pp. 1927-1939
◽
Keyword(s):
2017 ◽
Vol 9
(9)
◽
pp. 2923-2934
◽
2013 ◽
Keyword(s):